Clinical Trials | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
ELL will be the preferred source of supply for some the key Raw Materials to VPPL at "Arm's Length" transaction.
Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth
Amarex Clinical Research guides its client to phase II of FDA trials
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Subscribe To Our Newsletter & Stay Updated
